Saturday, 5 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

View original at globenewswire.com
Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study Bluffdale, UT, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Approximately 48% of respondents ranked fitness goals as their highest priority heading into the new year

    80% confidence

  • Approximately 12.4% of U.S. adults now report taking GLP-1 drugs for weight loss, more than double the 5.8% measured in February 2024

    80% confidence

  • Oral semaglutide 25 mg represents a significant advancement in obesity treatment

    80% confidence

  • About half of adults who have taken GLP-1 drugs reported difficulty affording the cost

    80% confidence

  • Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved medication

    80% confidence

  • Exercising more topped Americans' New Year's resolutions for 2026, with 25% of respondents listing it as their primary goal

    80% confidence

  • The agency is not aware of a basis for compounding using semaglutide sodium or semaglutide acetate salt forms

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study — Source | Via News | ViaNews EU